Table 2.
HER2 CN as a continuous variable was the independent predictor associated with DFS
| Characteristics | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Gender Male vs. female | 1.47 (0.18–11.74) | 0.719 | 2.39 (0.20–28.96) | 0.494 |
| Age ≥ 60 vs. < 60 years | 2.81 (0.58–13.63) | 0.198 | 6.67 (0.55–80.91) | 0.136 |
| Stage III vs. I/II | 3.59 (0.76–16.98) | 0.108 | 0.98 (0.08–11.79) | 0.985 |
| Histological grade poorly vs. well/moderately | 3.18 (0.67–15.03) | 0.145 | 9.41 (0.33–267.23) | 0.189 |
| Lauren’s classification intestinal vs. diffuse/mixed | 0.62(0.17–2.31) | 0.474 | 1.15 (0.12–10.72) | 0.900 |
| Perineural invasion positive vs. negative | 1.54 (0.38–6.15) | 0.543 | 0.37 (0.05–2.69) | 0.326 |
| Lymphatic/venous invasion positive vs. negative | 2.05 (0.52–8.07) | 0.303 | 7.24 (0.84–62.56) | 0.072 |
| Ulcer findings positive vs. negative | 2.09 (0.26–16.73) | 0.487 | 7.60 (0.24–239.13) | 0.249 |
| Tumor location distal vs. middle/proximal | 0.57 (0.12–2.75) | 0.483 | 0.78 (0.09–6.62) | 0.823 |
| HER2 CN | 1.02 (1.00–1.04) | 0.025 | 1.05 (1.01–1.09) | 0.029 |
DFS disease-free survival, HR hazard ratio, CI confidence interval, CN copy number, HER2: human epidermal growth factor receptor 2